s-1743 and Laryngeal-Diseases

s-1743 has been researched along with Laryngeal-Diseases* in 4 studies

Trials

2 trial(s) available for s-1743 and Laryngeal-Diseases

ArticleYear
[Repeated dual-probe pH monitoring as a diagnostic tool to control therapy for laryngopharyngeal reflux].
    HNO, 2007, Volume: 55, Issue:10

    The most effective current treatment option for patients suffering from laryngopharyngeal reflux (LPR) is the use of proton pump inhibitors (PPIs). Compared to other PPIs, esomeprazole seems to provide best 24-h control of intragastric acid. However, some patients remain resistant to medical acid suppression with PPIs. The aim of this investigation was to identify the number of non-responders among patients suffering from LPR being treated by esomeprazole 40 mg once daily (officially approved maximum dosage).. Between June 2004 and January 2006, 27 patients suffering from LPR diagnosed by dual-probe pH monitoring were treated with esomeprazole 40 mg once daily. After 13-54 days (mean 28 days) while still under PPI-treatment, the 24-h pH-study was repeated in order to control the effectiveness of therapy. Patients with at least a reduction of the reflux area index (RAI) compared to the result before treatment were categorized as responders. Furthermore, the number of patients with a measurable reduction of proximal reflux episodes under PPI-treatment was quantified.. Repeated pH monitoring during PPI therapy revealed a reduction of the RAI in 22 of 27 patients. Five patients, however, showed a higher RAI despite medical treatment (19%). In 13 patients (48%), treatment with 40 mg esomeprazole once daily reduced the RAI to a normal value (<6.3). In 18 of 27 patients, the number of proximal reflux episodes has decreased (67%).. In a number of patients suffering from LPR, treatment with esomeprazole 40 mg once daily did not provide any measurable proximal acid reduction. Repeated pH monitoring during treatment is an adequate diagnostic tool to control the therapeutic effect of PPIs objectively and to identify non-responders at an early point.

    Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Hypopharynx; Laryngeal Diseases; Male; Middle Aged; Pharyngeal Diseases; Prognosis; Treatment Outcome

2007
Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
    The Laryngoscope, 2003, Volume: 113, Issue:4

    Objectives were to determine the efficacy of empiric treatment with esomeprazole for patients diagnosed with laryngopharyngeal reflux and to determine a treatment paradigm for this patient population.. Prospective study.. Patients were treated with a once-daily dose of 40 mg esomeprazole for 8 weeks. All patients completed a subjective symptom scale (rating laryngeal symptoms and esophageal symptoms) and scoring of flexible fiberoptic examination before treatment and at 4 and 8 weeks of treatment. Nonresponders (<50% reduction in symptom score) were recommended to undergo 24-hour dual-probe pH study while on a regimen of 40 mg esomeprazole once a day, to evaluate for the adequacy of acid suppression.. Thirty patients completed the course of therapy. After 4 weeks of treatment, only 8 of 30 patients had significant improvement of their overall symptoms (8 of 30 improved on laryngeal score, and 11 of 18 improved on esophageal score). At 8 weeks of treatment, 19 of 30 patients had significant improvement on their overall symptoms (18 of 30 on laryngeal score, and 13 of 18 on their esophageal score). Five of seven nonresponders who agreed to be tested had positive findings on pH studies (on medication regimen) at 1 cm above the upper esophageal sphincter. Four of 10 nonresponders improved further after increasing their dosage to 40 mg twice a day. Laryngeal examination scores were statistically improved in responders after 8 weeks of treatment.. Laryngopharyngeal reflux symptoms require at least 8 weeks of treatment for significant improvement in the majority of patients. Esophageal symptoms improve sooner. Nonresponders at a daily dose of 40 mg should be treated with a dosage of 40 mg twice daily, and pH study on medication reserved for nonresponders at this higher dose. Laryngeal examination scores showed mild but statistically significant improvement at 8 weeks of therapy in responders.

    Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esomeprazole; Fiber Optic Technology; Follow-Up Studies; Gastroesophageal Reflux; Humans; Laryngeal Diseases; Pharyngeal Diseases; Prospective Studies; Severity of Illness Index; Treatment Outcome

2003

Other Studies

2 other study(ies) available for s-1743 and Laryngeal-Diseases

ArticleYear
Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care--a 5-year follow-up.
    Alimentary pharmacology & therapeutics, 2009, Jun-01, Volume: 29, Issue:11

    Gastro-oesophageal reflux disease (GERD) can be associated with laryngo-respiratory symptoms (LRS) such as chronic cough, asthma or laryngeal symptoms.. To analyse the long-term clinical course of LRS in a large population with GERD and LRS.. ProGERD is a prospective multicentre cohort study of 6215 adult out-patients with GERD. At baseline, the prevalence of LRS was assessed. Initial standardized treatment was esomeprazole for up to 8 weeks. After 5 years of follow-up, patients were interviewed for LRS and a multivariate analysis was performed with resolved vs. persistent symptoms for chronic cough, asthma and laryngeal symptoms.. In all, 2886 patients (46.4%) were available for analysis at baseline and at 5 years. The prevalence of chronic cough and laryngeal disorders had decreased while the prevalence of asthma had increased. Resolution of LRS was independent of clinical reflux characteristics or PPI medication.. In a large population with GERD, only few patients reported persistent LRS over 5 years. Resolution of LRS was independent of the stage of GERD and PPI treatment. Accordingly, data on the direction of causality between GERD and LRS are lacking and the strength of the association between the two must remain controversial.

    Topics: Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Esomeprazole; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Laryngeal Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Prevalence; Young Adult

2009
Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux.
    The Journal of laryngology and otology, 2004, Volume: 118, Issue:11

    Patients with gastroesophageal reflux disease may suffer from a variety of symptoms from the upper aerodigestive tract. The objective of this study was to determine the impact of dual-probe 24-hr pH monitoring in the diagnosis of reflux-related otolaryngological disorders.. Twenty-two patients with symptoms such as chronic cough, globus pharyngeus, heartburn, dysphonia and burning sensation of the tongue underwent a complete ear, nose and throat examination, 24-hr dual-probe pH monitoring, and oesophago-gastro-duodenoscopy.. pH monitoring revealed gastroesophageal (distal) reflux in all patients and pharyngeal (proximal) reflux in 21 patients. Treatment consisted of a proton pump inhibitor (esomeprazole). Within 4 weeks 68 per cent of patients had no laryngopharyngeal symptoms; within 8 weeks 95 per cent of patients were symptom-free.. Patients with atypical reflux symptoms such as hoarseness, globus sensation or throat-clearing responded well to anti-reflux treatment.

    Topics: Adult; Aged; Anti-Ulcer Agents; Cough; Endoscopy, Gastrointestinal; Esomeprazole; Female; Gastroesophageal Reflux; Hoarseness; Humans; Hydrogen-Ion Concentration; Laryngeal Diseases; Male; Middle Aged; Monitoring, Ambulatory

2004